Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
Date:2/28/2013

lude Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential future regulatory filings by AstraZeneca for naloxegol; the projected timing of the start of the Phase 3 clinical study by Bayer for Amikacin Inhale; the projected availability of Phase 2 clinical study results for NKTR-181; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from th
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
2. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
3. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... 29 AstraZeneca (NYSE: AZN ) announced today ... Delaware , has found that the substance patent protecting CRESTOR (RE37,314 – the ... no inequitable conduct was committed by any Shionogi employee. The court also held ... , , ...
... CINCINNATI, Ohio , June 29 Dr. Harry ... invited speaker and panel discussion participant at the 2010 Central Regional Meeting ... June 16-19, 2010 .  The 2010 CeRMACS attracted over 400 participants ... traditional chemical disciplines.   , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:12/19/2014)... death from "rat-bite fever" of a 10-year-old San Diego boy ... a report from the U.S. Centers for Disease Control and ... illness that should be considered in persons with rash, fever ... is reported," said a team led by Dr. Jessica Adam ... in the report occurred in August of 2013. Adam,s ...
(Date:12/19/2014)... Randy Dotinga ... News) -- Common painkillers, including ibuprofen, might slightly reduce ... researchers say. Use of ibuprofen (Advil, Motrin) and ... cell skin cancer by 15 percent, the researchers concluded ... is usually caused by sun exposure. ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
(Date:12/17/2014)... 2014 While countless companies tempt patients to ... the potential dangers of their purchase. Not only is the ... qualified doctor, but patients who buy hCG online are typically ... is actually no real hCG present. Illegal internet hCG is ... no safety standards and may contain unknown fillers that can ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
Breaking Medicine News(10 mins):Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... DDS, and her staff will be racing to save lives ... of Baltimore,s 2009 Susan G. Komen Race for the Cure. ... Team Chincheck has raised more than $4,700 for breast cancer ... affected by breast cancer and witnessing their strength and courage ...
... some parents may be lukewarm to the H1N1 vaccination, ... of Southern California,s largest integrated, comprehensive healthcare organizations, reports ... access to the vaccine. In response, Lakeside Community Healthcare ... patients direct access to the information they need to ...
... ... tourism industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. ... ... , a global health care company in the emerging medical tourism industry, announced the addition ...
... Oct. 14 Usinas,Siderurgicas de Minas Gerais S.A. - USIMINAS (OTC: USNZY) (BOVESPA: USIM3,USIM5, USIM6) ... Third Quarter 2009 Results Conference Call. Results will be, ... after Bovespa,s trading session., ... third quarter 2009 results, ...
... Peter Sheldon, Vice President of Operations for Coverall Health-Based ... will be a featured speaker at the Professional Retail ... on October 14-15 at The Fairmont Hotel in Dallas, ... Best in Your Business with Best Practices." Sheldon will ...
... Terumo ... the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd Annual ... , ... Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today ...
Cached Medicine News:Health News:Team Chincheck Goes Miles for Smiles 2Health News:Leading Southern California Physicians Report Patient Fears About Complexities of Flu Season 2Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Third Quarter 2009 Results Webcast 2Health News:Coverall Executive Peter Sheldon To Be Featured Speaker at PRSM Mid-Year Conference 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3
... This battery-powered, single-use, ... adjustable current settings: 0.5, ... uses a subdermal needle ... electrode. A "current flow" ...
... Versatile, pocket-size peripheral nerve ... a full-function nerve locator ... monitor, depending upon which ... attached. Includes NSL-5 electrode ...
Pocket-size digital nerve locator optimizes ease and convenience of performing peripheral nerve blocks. Includes RBW-5L electrode lead set, 9V alkaline battery, and durable molded polyethylene carryi...
The Lone Star Retractor System may be adapted to a specific region of the anatomy by simply adjusting the hinges. The system also includes multiple ring shapes, slots on perifephery of retractor ring...
Medicine Products: